SCHEMBL5147996

SCHEMBL5147996

CC(C)n1nc(-c2nc(C(N)=O)c(N)nc2-c2ccccc2Br)ccc1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.36
RET P07949 3/20 0.32
TP53 P04637 2/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 2/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GRM2 Q14416 1/20 0.32
AURKA O14965 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
PLK1 P53350 1/20 0.32
CCNA1 P78396 1/20 0.32
USP8 P40818 1/20 0.31
IKBKB O14920 1/20 0.31
FGFR1 P11362 1/20 0.30
FGFR2 P21802 1/20 0.30
FGFR4 P22455 1/20 0.30
FGFR3 P22607 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152934 0.92 ADORA2A (0.36) ADORA2ARETTP53LMNAPOLB
SCHEMBL5149097 0.85 RET (0.41) ADORA2ARETTP53POLBAURKA
SCHEMBL5152629 0.85 RET (0.41) ADORA2ARETTP53POLBAURKA
SCHEMBL5149248 0.84 USP8 (0.51) ADORA2AUSP8IKBKBFGFR1FGFR2
SCHEMBL5149205 0.84 USP8 (0.51) ADORA2AUSP8IKBKBFGFR1FGFR2
SCHEMBL5152804 0.80 MAP2K3 (0.41) ADORA2ARETMAPT
SCHEMBL5152670 0.80 ADORA2A (0.38) ADORA2AFGFR1FGFR2FGFR3HSD17B10
SCHEMBL5149225 0.80 RET (0.45) ADORA2ARETPOLBMAPTTDP1
SCHEMBL5152877 0.79 FGFR1 (0.36) ADORA2ARETTP53LMNAPOLB
SCHEMBL5152750 0.79 ADORA2A (0.45) ADORA2ARETKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 ADORA2A 1/4885RET 2434/4885TP53 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.